Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSystem1 Group Regulatory News (SYS1)

Share Price Information for System1 Group (SYS1)

Share Price is delayed by 15 minutes
Get Live Data
329.00    0.00 (0.00%)
Bid:
322.00
Ask:
336.00
Spread: 14.00 (4.348%)
Market Cap: £41.75m
SYS1 Live PriceLast checked at - London Stock Exchange

Intraday System1 Group Share Chart

Trading Update

21 Apr 2021 07:00

RNS Number : 0916W
System1 Group PLC
21 April 2021
 

21 April 2021

 

SYSTEM1 GROUP PLC (AIM: SYS1)

("System1", or "the Company", or "the Group")

 

 

Year End Trading Update

 

 

System1 Group, the Advertising Effectiveness Agency, is today providing a Trading Update for its financial year to the end of March 2021 ahead of its results announcement on 29 June 2021.

 

12 MONTHS TO END-MARCH 2021

 

Our Interim Statement released on 17 November 2020 reported that Revenue and Adjusted Profit had recovered substantially since Q1 and that the sales pipeline was strong. This improvement was maintained throughout the second half-year such that Revenue in H2 was approximately 8% above that of the equivalent prior year period, compared with a 26% decline in H1. As a result, the full year Revenue reduction was 11%.

Profitability was stronger in H2 than in H1 as sales picked up faster than adjusted operating costs which were 16% lower than last year in the second half.

We expect to report a pre-tax Adjusted Profit (which excludes impairment, share-based payments, government support, bonuses, loan interest and certain provisions) of some £2.9m for the full year (FY 2019/20: £2.0m). The business continued to generate cash, ending the period with £6.5m cash net of debt versus £4.2m at the previous year end. The net cash figure does not include a £0.5m tax credit for FY 2019/20 which was received early in April 2021.

Underlying the recent improvement is the success of Test Your Ad, System1's first fully automated predictive product set. The transition to automated data products supported by data-enabled, repeatable consultancy products is well underway: data products represented 15% of Sales Revenue in Q4 - mainly Test Your Ad - compared with 1% in H1. We expect the proportion of data product revenues to increase with the rollout in 2021/22 of Test Your Brand.

With the resumption of sales growth and a strong net cash position, the Company will look to reinstate the share buyback programme which was suspended in 2020 due to uncertainty over the potential impact of the Covid pandemic on our business. A return to dividend payments is not currently envisaged. More information will be provided on the proposed buyback later in the year.

 

OUTLOOK

System1 is focused on achieving Revenue growth over the short and medium term. In pursuit of this goal the Company will increase discretionary investment in product development, IT, marketing, and relationships with advertising agencies and advertising platform partners. We will also continue to recruit new talent, after a sizeable increase in headcount during the latter months of 2020/21 which took year-end headcount to 147 from 128 at the half year. The drive for further efficiency improvements in "run" costs will continue. We plan to remain profitable and to continue to generate cash in the 2021/22 financial year, notwithstanding that we are targeting revenue growth to be at least matched by the rate of cost growth as we prioritise scaling our automated predictive products.

 

The Company can be found at https://system1group.com/

 

This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication of this announcement, this information is now considered to be in the public domain. 

 

For further information, please contact:

 

System1 Group PLC

Tel: +44 (0)20 7043 1000

John Kearon, Founder & Executive President

Stefan Barden, Chief Executive Officer

Chris Willford, Chief Financial Officer

Canaccord Genuity Limited

Tel: +44 (0)20 7523 8000

Simon Bridges / Andrew Potts

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTURABRAKUSUAR
Date   Source Headline
7th Jan 20227:00 amRNSShare Buyback Programme
4th Jan 20222:00 pmRNSDirectorate Change
30th Nov 20214:51 pmRNSDirector Dealings
30th Nov 20217:00 amRNSINTERIM RESULTS
9th Nov 20217:00 amRNSComplaint for Trademark Infringement
29th Oct 20211:24 pmRNSGrant of Options
20th Oct 20217:00 amRNSTrading Update
13th Aug 20215:24 pmRNSAnnual General Meeting
13th Aug 20217:00 amRNSTrading Update for the Annual General Meeting
4th Aug 20216:15 pmRNSUpdate re 2021 AGM
20th Jul 20212:30 pmRNSAnnual Report and Notice of AGM
14th Jul 20217:00 amRNSFinal Results
23rd Jun 202112:30 pmRNSNotice of Results
21st May 20217:00 amRNSExercise of Options and Total Voting Rights
17th May 202112:12 pmRNSDirector/PDMR Shareholding
28th Apr 20211:08 pmRNSDirector/PDMR Shareholding
23rd Apr 202111:16 amRNSCorrection re Directors Dealings
23rd Apr 20219:40 amRNSExercise of Options, Directors Dealings and TVR
21st Apr 20217:00 amRNSTrading Update
30th Mar 20217:00 amRNSChange in Executive Job Titles
15th Feb 202112:42 pmRNSBoard Changes
12th Feb 202111:00 amRNSPrice Monitoring Extension
20th Jan 20217:00 amRNSDirector/PDMR Shareholding
2nd Dec 20204:30 pmRNSGrant of Options
27th Nov 20207:00 amRNSDirector/PDMR Shareholding
17th Nov 20206:27 pmRNSDirector/PDMR Shareholding
17th Nov 20207:00 amRNSInterim Results
14th Oct 20207:00 amRNSTrading Update
12th Oct 20201:40 pmRNSHolding(s) in Company
7th Oct 20202:33 pmRNSHolding(s) in Company
24th Sep 20204:08 pmRNSHolding(s) in Company
4th Aug 20209:39 amRNSDirector/PDMR Shareholding - Replacement
3rd Aug 20205:33 pmRNSDirector/PDMR Shareholding
31st Jul 20206:34 pmRNSResult of AGM
6th Jul 20204:33 pmRNSAnnual Report and Notice of AGM
3rd Jul 202012:22 pmRNSDirector/PDMR Shareholding
2nd Jul 202010:04 amRNSDirector/PDMR Shareholding
30th Jun 20207:00 amRNSFinancial results to 31 March 2020
26th Jun 20202:00 pmRNSExercise of Options and Total Voting Rights
26th Jun 20207:00 amRNSDirectorate Change
26th Jun 20207:00 amRNSDirectorate Change
27th Apr 20207:00 amRNSTrading Update
3rd Apr 20207:00 amRNSChief Financial Officer Resignation
24th Mar 20204:40 pmRNSSecond Price Monitoring Extn
24th Mar 20204:36 pmRNSPrice Monitoring Extension
6th Feb 20207:00 amRNSTrading Update and Planned Share Buyback
23rd Dec 20193:30 pmRNSExercise of Options and Total Voting Rights
7th Nov 20199:29 amRNSDividend Declaration
7th Nov 20197:00 amRNSInterim Results
14th Oct 20197:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.